In a move that hasn't been seen since the medical community fought to remove lead from household paints and gasoline, several national health organizations have joined a lawsuit against the Environmental Protection Agency alleging that a finalized rule on mercury emissions fails to protect fetuses and children from the toxin's harm.
In a move that hasn't been seen since the medical community fought to remove lead from household paints and gasoline, several national health organizations have joined a lawsuit against the Environmental Protection Agency alleging that a finalized rule on mercury emissions fails to protect fetuses and children from the toxin's harm. The health groups are challenging the EPA's decision to provide an exemption to coal- and oil-fired power plants-the nation's largest source of mercury emissions-from the Clean Air Act.
The Clean Air Act requires power plants to "use the best available technology to reduce mercury emissions," according to The Journal of the American Medical Association (7/27/05). This requirement would have reduced mercury emissions from plants by 90% by 2008. However, the EPA's final rule allows power plants to reduce emissions by about 24% by 2010, and then 70% by 2018.
It's estimated that as many as 637,233 infants each year are born with cord blood mercury levels greater than 5.8 mg/L. This mercury level has been associated with the loss of IQ; methyl mercury also contributes to developmental delays and learning disabilities.
Thinner endometrial thickness linked to higher placenta accreta spectrum risk
November 29th 2024A recent study reveals that reduced endometrial thickness significantly increases the risk of placenta accreta spectrum disorders in women without prior cesarean deliveries using assisted reproductive technology.
Read More
Emerging multiplex UTI testing drives Medicare costs amid increased utilization
November 27th 2024A recent study found a sharp rise in Medicare claims for multiplex urinary tract infection testing from 2016 to 2023, underscoring a significant financial impact and the need for further research into its clinical benefits.
Read More
Reduced cost-effectiveness reported from HPV vaccination in mid-adults
November 27th 2024A recent study highlights the reduced cost-effectiveness of expanding human papillomavirus vaccination to adults aged 27 to 45 years compared to younger groups, though targeted strategies for high-risk subgroups indicate benefits.
Read More